Cargando…
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Atopic dermatitis (AD) is a common, heterogeneous, inflammatory skin disorder characterized by chronic or relapsing eczematous lesions with intense pruritus and discomfort. Affected patients often experience significant impairment in their quality of life, and the treatment of moderate-to-severe AD...
Autores principales: | Bernardo, Diana, Bieber, Thomas, Torres, Tiago |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460333/ https://www.ncbi.nlm.nih.gov/pubmed/37266844 http://dx.doi.org/10.1007/s40257-023-00793-5 |
Ejemplares similares
-
Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis
por: Loh, Tiffany Y, et al.
Publicado: (2020) -
Managing Atopic Dermatitis with Lebrikizumab – The Evidence to Date
por: Labib, Angelina, et al.
Publicado: (2022) -
Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials
por: Stein Gold, Linda, et al.
Publicado: (2023) -
The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
por: Bashrahil, Bader, et al.
Publicado: (2023) -
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere)
por: Simpson, Eric L., et al.
Publicado: (2023)